{"entity":{"id":"nct04879329","kind":"trial","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","aka":[],"tldr":"A phase 2 trial of Disitamab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, now recruiting.","summary":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 is a phase 2 interventional study registered as NCT04879329 by Seagen, a wholly owned subsidiary of Pfizer, with 372 participants planned, started 2022-05-03 and due to reach its primary completion in 2026-12-11. Interventions recorded: disitamab vedotin and pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04879329","url":"https://clinicaltrials.gov/study/NCT04879329"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["disitamab-vedotin","pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04879329","phase":"2","setting":"A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","enrolled":372,"outcomes":[]},"route":"/trials/nct04879329/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}